Targeting DLK1 in neuroblastoma
1UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.
Cancer Cell
|November 1, 2024
Abstract:
An ideal cell surface target has ubiquitously high cancer expression, absence from healthy tissues, and an essential role cancer initiation and/or maintenance. In this issue of Cancer Cell, Hamilton et al. combine proteomics, transcriptomics, epigenomics, and dependency databases to identify DLK1, a novel immunotherapeutic target for neuroblastoma.
Insights
Researchers identified DLK1 as a promising new target for neuroblastoma immunotherapy. This cell surface protein is highly expressed in cancer cells but not healthy tissues, making it ideal for treatment.
Area of Science:
- Oncology
- Immunotherapy
- Genomics
Background:
- Identifying effective cancer cell surface targets is crucial for developing targeted therapies.
- Ideal targets exhibit high expression on cancer cells and minimal presence on healthy tissues.
- Such targets should also play a critical role in cancer initiation or maintenance.
Purpose of the Study:
- To identify a novel immunotherapeutic target for neuroblastoma.
- To find a cell surface protein with ideal characteristics for cancer therapy.
Main Methods:
- Utilized a multi-omics approach, integrating proteomics, transcriptomics, and epigenomics data.
- Analyzed dependency databases to assess the essentiality of potential targets.
- Combined various datasets to identify candidate targets.
Main Results:
- Identified Delta-like 1 homolog (DLK1) as a novel target for neuroblastoma.
- DLK1 demonstrates ubiquitous high expression in neuroblastoma.
- DLK1 is absent from healthy tissues, fulfilling key criteria for an ideal therapeutic target.
Conclusions:
- DLK1 represents a promising and novel immunotherapeutic target for neuroblastoma.
- The findings support the potential of DLK1-targeted therapies for treating neuroblastoma.
